Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Japanese Journal of Ophthalmology
Published in: Japanese Journal of Ophthalmology 1/2017

01-01-2017 | Clinical Investigation

Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration

Authors: Masaaki Saito, Mariko Kano, Kanako Itagaki, Tetsuju Sekiryu

Published in: Japanese Journal of Ophthalmology | Issue 1/2017

Login to get access

Abstract

Purpose

To clarify the efficacy of aflibercept for treating exudative age-related macular degeneration (AMD).

Methods

We prospectively studied 47 eyes with AMD. Forty-seven patients (mean age 72.2 years) received three consecutive monthly intravitreal aflibercept injections followed by an injection every 2 months until 12 months. The primary outcome was the 12-month visual results compared with baseline; the secondary outcomes were the prevalence of geography atrophy (GA), a dry macula at month 12, and anatomic changes on optical coherence tomography.

Results

The mean logarithm of the minimum angle of resolution best-corrected visual acuity (BCVA) in 27 eyes with typical AMD and 20 eyes with polypoidal choroidal vasculopathy (PCV) significantly (p < 0.0001, p < 0.05, respectively) improved from 0.60 to 0.32 at baseline to 0.29 and 0.21 at month 12. At month 12, 22 (81.5 %) eyes with typical AMD and 17 (85 %) eyes with PCV had dry macula. The subfoveal choroidal thicknesses in typical AMD and PCV decreased significantly (p < 0.0001 for both comparisons) from 241 ± 118 and 294 ± 76 μ at baseline to 198 ± 104 and 244 ± 84 μ at month 12. Progressing or new GA was seen in three eyes with typical AMD and one eye with PCV; the mean change in the BCVA was significantly (p = 0.0026) worse at month 12. No other complications developed.

Conclusion

Intravitreal aflibercept significantly improved VA and anatomic changes in typical AMD and PCV over 12 months. Development of GA might be a risk for declining VA.
Literature
1.
Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640–2.CrossRefPubMed
2.
Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol. 1991;109:1220–31.CrossRef
3.
Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Am J Ophthalmol. 1994;118:285–98.CrossRefPubMed
4.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, MARINA Study Group, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419–31.CrossRefPubMed
5.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY, et al. ANCHOR Study Group Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432–44.CrossRefPubMed
6.
Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QD, VIEW 1 and VIEW 2 Study Groups, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:2537–48.CrossRefPubMed
7.
Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). Retina. 1990;10:1–8.CrossRefPubMed
8.
Imamura Y, Engelbert M, Iida T, Freund KB, Yannuzzi LA. Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol. 2010;55:501–15.CrossRefPubMed
9.
Maruko I, Iida T, Saito M, Nagayama D, Saito K. Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol. 2007;144:15–22.CrossRefPubMed
10.
Lafaut BA, Leys AM, Snyers B, Rasquin F, De Laey JJ. Polypoidal choroidal vasculopathy in Caucasians. Graefes Arch Clin Exp Ophthalmol. 2000;238:752–9.CrossRefPubMed
11.
Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H, et al. EVEREST Study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina. 2012;32:1453–64.CrossRefPubMed
12.
Inoue M, Arakawa A, Yamane S, Kadonosono K. Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy. Retina. 2014;34:2178–84.CrossRefPubMed
13.
Saito M, Kano M, Itagaki K, Oguchi Y, Sekiryu T. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina. 2014;34:2192–201.CrossRefPubMed
14.
Koizumi H, Kano M, Yamamoto A, Saito M, Maruko I, Sekiryu T, et al. Aflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre study. Br J Ophthalmol. 2015;99:1284–8.CrossRefPubMed
15.
Yamamoto A, Okada AA, Kano M, Koizumi H, Saito M, Maruko I, et al. Intravitreal aflibercept for polypoidal choroidal vasculopathy. Ophthalmology. 2015;122:1866–72.CrossRefPubMed
16.
Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120:2292–9.CrossRefPubMed
17.
Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Maguire MG, Fine SL, Ying GS, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388–98.CrossRef
18.
Tano Y, Ohji M, Ishibashi T, Shiraga F, Tokoro T, Yuzawa M, et al. Re-treatment guideline of ranibizumab (genetical recombination) in the maintenance phase. Nippon Ganka Gakkai Zasshi. 2009;113:1098–103 (In Japanese).PubMed
19.
Saito M, Iida T, Kano M. Intravitreal ranibizumab for exudative age-related macular degeneration with good baseline visual acuity. Retina. 2012;32:1250–9.CrossRefPubMed
20.
Oishi A, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Nakanishi H, et al. One year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcome. Am J Ophthalmol. 2015;159:853–60.CrossRefPubMed
21.
Saito M, Kano M, Itagaki K, Ise S, Imaizumi K, Sekiryu T. subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection. Jpn J Ophthalmol. 2016;60:35–41.CrossRefPubMed
22.
Julien S, Biesemeier A, Taubitz T, Schraermeyer U. Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyes. Br J Ophthalmol. 2014;98:813–25.CrossRefPubMed
23.
Elman MJ, Fine SL, Murphy RP, Patz A, Auer C. The natural history of serous retinal pigment epithelium detachment in patients with age-related macular degeneration. Ophthalmology. 1986;93:224–30.CrossRefPubMed
24.
Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol. 2008;92:1642–7.CrossRefPubMed
25.
Cho HJ, Kim KM, Kim HS, Lee DW, Kim CG, Kim JW. Response of pigment epithelial detachment to anti-vascular endothelial growth factor treatment in age-related macular degeneration. Am J Ophthalmol. 2016;166:112–9 (Epub ahead of print).CrossRefPubMed
26.
Klein R, Klein BE, Franke T. The relationship of cardiovascular disease and its risk factors to age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology. 1993;100:406–14.CrossRefPubMed
27.
Sunness JS, Margalit E, Srikumaran D, Applegate CA, Tian Y, Perry D, et al. The long-term natural history of geographic atrophy from age-related macular degeneration: enlargement of atrophy and implications for interventional clinical trials. Ophthalmology. 2007;114:271–7.CrossRefPubMedPubMedCentral
28.
Kuroda Y, Yamashiro K, Tsujikawa A, Ooto S, Tamura H, Oishi A, et al. Retinal pigment epithelial atrophy in neovascular age-related macular degeneration after ranibizumab treatment. Am J Ophthalmol. 2016;161(94–103):e1.
Metadata
Title
Efficacy of intravitreal aflibercept in Japanese patients with exudative age-related macular degeneration
Authors
Masaaki Saito
Mariko Kano
Kanako Itagaki
Tetsuju Sekiryu
Publication date
01-01-2017
Publisher
Springer Japan
Published in
Japanese Journal of Ophthalmology / Issue 1/2017
Print ISSN: 0021-5155
Electronic ISSN: 1613-2246
DOI
https://doi.org/10.1007/s10384-016-0478-5

Other articles of this Issue 1/2017

Japanese Journal of Ophthalmology 1/2017 Go to the issue

Clinical Investigation

Eyelid cleansing with ointment for obstructive meibomian gland dysfunction

Clinical Investigation

Comparison between ranibizumab and aflibercept for macular edema associated with central retinal vein occlusion

Clinical Investigation

Effect of vitreomacular separation on macular thickness determined by spectral-domain optical coherence tomography

Clinical Investigation

Clinical practice pattern in management of diabetic macular edema in Japan: survey results of Japanese retinal specialists

Review

A new era of uveitis: impact of polymerase chain reaction in intraocular inflammatory diseases

Clinical Investigation

The effect of the extent of the incision in the Schlemm canal on the surgical outcomes of suture trabeculotomy for open-angle glaucoma